Medtronic begins U.S. clinical evaluations of implantable cardioverter defibrillator – Brief Article
Medtronic, Inc., Minneapolis, completed the first human implant in the U.S. of its InSync ICD (implantable cardioverter defibrillator) designed to treat patients with heart failure and who are at risk of sudden cardiac death from too-fast heart rates.
The InSync combines two therapies into one system. It was developed to provide detection and treatment of life-threatening tachyarrhythmias from the right side of the heart and at the same time deliver advanced cardiac resynchronization therapy. Cardiac Resynchronization therapy is intended to restore left and right ventricular synchrony by simultaneously pacing both ventricles and improve the heart’s pumping efficiency in heart failure patients.
In a large, double-blinded U.S. clinical trial called MIRACLE ICD, physicians will evaluate the performance of the combined therapy product.
COPYRIGHT 1999 J.B. Lippincott Company
COPYRIGHT 2000 Gale Group